Yarrow Bioscience launches underwritten follow-on stock offering
YARW•Follow-on offering and use of proceeds
Yarrow Bioscience launched an underwritten public offering of common stock, with pre-funded warrants available in lieu of shares.
Underwriters will have a 30-day option to buy up to 15% more shares at the offering price, net of discounts.
Proceeds are earmarked for R&D across the pipeline, with remaining funds for general corporate purposes.
Jefferies, TD Cowen and Guggenheim Securities were named joint bookrunners, and LifeSci Capital was set as lead manager.
